Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ENTX vs ICCC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ICCC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)
ICCC Overall Winner
6-Pillar Tally: ENTX 1 – 5 ICCC
Matrix Metrics: ENTX 3 – 6 ICCC
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin).
- Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. -100.0% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ENTX vs ICCC
ENTX
Entera Bio Ltd. Ordinary Shares
$3.02
-2.89% 1D
Market Cap
$541.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.07β · 46% Vol
Unified Composite Score
53.9
HOLD
Tech 37.0
Fund 54.0
Flow 72.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ICCC
Head-to-Head Winner
Immucell Corp
$11.42
+6.23% 1D
Market Cap
$97.7M
TTM Revenue
$67M
Forward P/E
N/M
Beta / 30D Vol
0.24β · 46% Vol
Unified Composite Score
43.8
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ENTX 1 – 5 ICCC)
1. Valuation Multiples
ICCC
Forward P/E
N/M
N/M
Trailing P/E
N/M
56.6x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
1.6x
2. Growth & Scale
ICCC
Revenue Growth (YoY)
-100.0%
+11.5%
Earnings Growth (YoY)
+0.0%
+259.9%
TTM Revenue (USD)
N/A
$67M
Market Cap
$541.6M
$97.7M
3. Profitability & Quality
ICCC
Gross Margin
N/A
40.3%
Operating Margin
0.0%
15.2%
Net Profit Margin
0.0%
2.6%
Return on Equity (ROE)
-20.3%
2.6%
4. Balance Sheet & Cash Flow
ICCC
Cash Generation (TTM)
-$16M
$7.4M
Cash Flow Margin
N/A
11.0%
Net Cash / Leverage
$265M Net Cash
$13M Net Debt (0.44x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
113.8% (32nd %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
ICCC
OpEx & R&D Intensity
N/A
25.1% of Rev ($17M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENTX (3) vs ICCC (6)| Institutional Metric | ENTX | ICCC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $541.6M | $97.7M | ENTX | |
| Trailing P/E Ratio | N/M | 56.6x | ICCC | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -100.0% | +11.5% | ICCC | |
| Operating Margin (TTM) | 0.0% | 15.2% | ICCC | |
| Net Profit Margin | 0.0% | 2.6% | ICCC | |
| Return on Equity (ROE) | -20.3% | 2.6% | ICCC | |
| 52-Week Range Position | 64% ($1–$4) | 91% ($5–$12) | ICCC | |
| Beta / 30D Volatility | 1.07β · 46% Vol | 0.24β · 46% Vol | ENTX | |
| Unified Institutional Score | 53.9 / 100 (HOLD) | 43.8 / 100 (HOLD) | ENTX | |
| Trailing 12M Revenue (USD) | N/A | $67M | Scale | |
| Gross Profit Margin (TTM) | N/A | 40.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 1.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$16M ($265M Net Cash) | $7.4M ($13M Net Debt (0.44x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENTX +6.46 pp
3M Horizon
ICCC +12.51 pp
6M Horizon
ENTX +130.29 pp
1Y Horizon
ICCC +78.54 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | ICCC Revenue | ENTX Op. Margin | ICCC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -13.2% | ICCC |
| FY2019 | N/A | $10M | N/A | -7.0% | ICCC |
| FY2020 | $0M | $20M | -3059.7% | -9.0% | ICCC |
| FY2021 | $0M | $20M | -2139.6% | 1.3% | ICCC |
| FY2022 | $0M | $20M | -9714.2% | -12.4% | ICCC |
| FY2023 | N/A | $20M | N/A | -32.9% | ICCC |
| FY2024 | $0M | $30M | -5295.6% | -6.2% | ICCC |
| FY2025 | $0M | $30M | -27450.0% | 6.0% | ICCC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ENTX
CONSOLIDATION
Current IV
113.8%
IV Percentile
32nd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ICCC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ICCC Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
OpEx & R&D Reinvestment
25.1% of Rev ($17M)
90D Engineering Disclosures
0 Published
Investor FAQ ENTX vs ICCC Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ENTX carries a Unified Composite Score of 53.9/100 (HOLD) at $3.02 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin). Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (53.9/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.2% vs. 0.0% operating margin) and revenue trajectory (+11.5% vs. -100.0% YoY).
ICCC leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ICCC at +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTX cumulative revenue shifted N/A while ICCC shifted +200.0%. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($17M) (0 disclosures) for ICCC.
ICCC screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus ICCC (2.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk). By comparison, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ICCC vs ENTX · Reverse Pair
ENTX vs IMMP
· Sector Peer
ICCC vs CSBR
· Sector Peer
ICCC vs INTG
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking